John G. Ullman & Associates’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

John G. Ullman & Associates’s Portfolio WX Stock Details WX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-7,972	Closed	-$268K	–	148
2014 Q4	$268K	Sell	7,972 -100	-1%	-$3.53K	0.05%	132
2014 Q3	$283K	Sell	8,072 -250	-3%	-$8.57K	0.05%	129
2014 Q2	$273K	Sell	8,322 -600	-7%	-$20.5K	0.05%	133
2014 Q1	$329K	Sell	8,922 -7,428	-45%	-$273K	0.06%	126
2013 Q4	$628K	Sell	16,350 -8,750	-35%	-$276K	0.12%	119
2013 Q3	$688K	Sell	25,100 -15,600	-38%	-$370K	0.14%	117
2013 Q2	$855K	Buy	+40,700	New	+$795K	0.18%	103

Other funds holding WX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

CGI

Comgest Global Investors Paris, France $4.59B AUM 12.96% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

John G. Ullman & Associates's WX Position: Q1 2015 in Review

John G. Ullman & Associates sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q1 2015, closing a stake of 7,972 shares — an estimated $268K sold.

John G. Ullman & Associates first reported a position in WX in Q2 2013 and held it in 7 quarters. The position peaked at $855K in Q2 2013. 147 funds tracked by Wall St. Rank hold WX as of Q1 2015.

John G. Ullman & Associates reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q1 2015 after selling out during the quarter.
John G. Ullman & Associates sold 7,972 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q1 2015, an estimated $268K.
John G. Ullman & Associates first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 7 quarters.
John G. Ullman & Associates's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $855K in Q2 2013.
147 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q1 2015.

Based on John G. Ullman & Associates's 13F filing for Q1 2015, filed 13 May 2015.